In this section
@article{Yang:2023:10.3390/pharmaceutics15030797,
author = {Yang, Y and Gu, B and Xu, X},
doi = {10.3390/pharmaceutics15030797},
journal = {Pharmaceutics},
pages = {1--14},
title = {In silico study of different thrombolytic agents for fibrinolysis in acute ischemic stroke},
url = {http://dx.doi.org/10.3390/pharmaceutics15030797},
volume = {15},
year = {2023}
}
TY - JOUR
AB - Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy by computational simulations of the pharmacokinetics and pharmacodynamics combined with a local fibrinolysis model. The performances of the drugs are evaluated by comparing clot lysis time, plasminogen activator inhibitor (PAI) inhibition resistance, intracranial hemorrhage (ICH) risk, and activation time from drug administration to clot lysis. Our results reveal that urokinase has the quickest lysis completion but the highest ICH risk due to excess fibrinogen depletion in systemic plasma. While tenecteplase and alteplase have very similar thrombolysis efficacy, tenecteplase has a lower risk of ICH and better resistance to PAI-1. Among the four simulated drugs, reteplase has the slowest fibrinolysis rate, but fibrinogen concentration in systemic plasma is unaffected during thrombolysis.
AU - Yang,Y
AU - Gu,B
AU - Xu,X
DO - 10.3390/pharmaceutics15030797
EP - 14
PY - 2023///
SN - 1999-4923
SP - 1
TI - In silico study of different thrombolytic agents for fibrinolysis in acute ischemic stroke
T2 - Pharmaceutics
UR - http://dx.doi.org/10.3390/pharmaceutics15030797
UR - https://www.mdpi.com/1999-4923/15/3/797
UR - http://hdl.handle.net/10044/1/103352
VL - 15
ER -
Room 1M17, ACE Extension Building
Department of Chemical Engineering
Imperial College London, South Kensington Campus
London, SW7 2AZ, UK
Tel: +44 (0)207 594 2562